Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Sees Large Increase in Short Interest

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) was the recipient of a significant growth in short interest in May. As of May 29th, there was short interest totaling 45,360 shares, a growth of 67.7% from the May 14th total of 27,047 shares. Based on an average trading volume of 165,199 shares, the short-interest ratio is currently 0.3 days. Currently, 1.0% of the company’s shares are sold short.

Hedge Funds Weigh In On Sonoma Pharmaceuticals

An institutional investor recently bought a new position in Sonoma Pharmaceuticals stock. McKinley Carter Wealth Services Inc. purchased a new position in shares of Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 11,193 shares of the company’s stock, valued at approximately $41,000. McKinley Carter Wealth Services Inc. owned approximately 0.66% of Sonoma Pharmaceuticals at the end of the most recent quarter. 1.95% of the stock is owned by institutional investors.

Sonoma Pharmaceuticals Stock Performance

NASDAQ:SNOA traded up $0.01 during trading hours on Wednesday, reaching $1.11. The company’s stock had a trading volume of 99,740 shares, compared to its average volume of 127,134. The company has a market capitalization of $5.29 million, a P/E ratio of -0.54 and a beta of 1.29. Sonoma Pharmaceuticals has a 12 month low of $0.85 and a 12 month high of $6.92. The stock has a 50 day moving average price of $1.44 and a two-hundred day moving average price of $2.50.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last issued its quarterly earnings data on Tuesday, June 16th. The company reported ($0.33) EPS for the quarter. The business had revenue of $5.56 million during the quarter. Sonoma Pharmaceuticals had a negative return on equity of 42.56% and a negative net margin of 19.04%.

Analyst Ratings Changes

Separately, Weiss Ratings downgraded shares of Sonoma Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, April 29th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Sonoma Pharmaceuticals currently has an average rating of “Sell”.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc is a specialty dermatology company focused on developing and commercializing topical prescription and over-the-counter products for inflammatory and infectious skin conditions. Publicly traded on Nasdaq under the symbol SNOA, the company concentrates its efforts on areas such as acne, rosacea, dermatitis and wound care, aiming to provide physicians and patients with innovative treatment options.

At the heart of Sonoma’s technology platform lies its proprietary Triphasic drug delivery system, which enables the timed release of active ingredients through three distinct gel phases.